Agomab Appoints Marino Garcia and Dr. Naimish Patel to Board

Antwerp, Belgium, September 11, 2026 /CourierPR/ -- Agomab Therapeutics NV, a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases, has announced the appointment of Marino Garcia and Dr. Naimish Patel, M.D., to its Board of Directors. The appointments were approved by shareholders at the company's Special and Extraordinary General Shareholders' Meeting held on September 11, 2026.

Tim Knotnerus, Chief Executive Officer of Agomab, expressed gratitude for the support of the shareholders and highlighted the significance of the appointments.

Marino Garcia, a seasoned executive with extensive experience in the pharmaceutical industry, commented, "I am honored to join Agomab's Board at such an exciting stage in the Company's development. Agomab has built a compelling pipeline targeting fibro-inflammatory diseases with significant unmet need, supported by a talented leadership team and strong scientific foundation. I look forward to working closely with the Board and management team to help advance the Company's strategy and long-term vision."

Dr. Naimish Patel, M.D., added, "I am delighted to join Agomab's Board and contribute to the Company's mission of developing innovative therapies for patients with fibro-inflammatory diseases. The combination of strong science, clear clinical focus, and commitment to addressing significant unmet medical needs creates an exciting opportunity. I look forward to bringing my experience in translational medicine and clinical development to support Agomab's continued progress."

The appointments come as Agomab continues to advance its pipeline of potential disease-modifying therapies. The company is focused on addressing the high unmet medical need in fibro-inflammatory diseases, utilizing organ-restricted approaches to increase efficacy while minimizing safety liabilities.

In addition to the Board appointments, the shareholders also approved the proposed consolidation and split adjustment of outstanding pre-IPO warrants, aligning such warrants with the share split implemented in connection with Agomab's IPO in February 2026.

Agomab's mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function, enabling people with these disorders to live fuller and healthier lives. The company's pipeline includes several promising candidates, each designed to target established, potent pathways with the potential to deliver meaningful benefits to patients.

With the addition of Garcia and Patel to the Board, Agomab is well-positioned to continue its mission and advance its portfolio of potential disease-modifying therapies. The company remains committed to creating meaningful value for patients and shareholders alike.